IRIS
PIRISI, Mario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 8.732
NA - Nord America 6.728
AS - Asia 2.122
SA - Sud America 28
Continente sconosciuto - Info sul continente non disponibili 21
AF - Africa 14
OC - Oceania 11
Totale 17.656
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.678
IE - Irlanda 2.755
IT - Italia 1.337
SE - Svezia 1.268
DE - Germania 1.115
UA - Ucraina 887
FR - Francia 658
HK - Hong Kong 598
CN - Cina 554
SG - Singapore 423
FI - Finlandia 387
IN - India 310
CZ - Repubblica Ceca 128
GB - Regno Unito 85
VN - Vietnam 63
IR - Iran 55
CA - Canada 47
BE - Belgio 39
TR - Turchia 34
KR - Corea 22
EU - Europa 20
NL - Olanda 16
RU - Federazione Russa 14
JP - Giappone 11
PK - Pakistan 11
AU - Australia 9
CL - Cile 9
PE - Perù 8
PL - Polonia 8
RO - Romania 8
MY - Malesia 7
PH - Filippine 7
CH - Svizzera 6
KE - Kenya 6
BR - Brasile 5
ES - Italia 5
BD - Bangladesh 4
CO - Colombia 4
EG - Egitto 4
ID - Indonesia 4
MO - Macao, regione amministrativa speciale della Cina 4
GR - Grecia 3
SA - Arabia Saudita 3
TH - Thailandia 3
TW - Taiwan 3
AR - Argentina 2
BG - Bulgaria 2
CU - Cuba 2
IL - Israele 2
IQ - Iraq 2
LI - Liechtenstein 2
LT - Lituania 2
LY - Libia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
RS - Serbia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AT - Austria 1
JO - Giordania 1
KH - Cambogia 1
MK - Macedonia 1
NG - Nigeria 1
PA - Panama 1
PT - Portogallo 1
SN - Senegal 1
Totale 17.656
Salva come PNG Salva come JPEG
Città #
Dublin 2.737
Jacksonville 1.663
Dearborn 737
Chandler 604
Hong Kong 586
Wilmington 432
Princeton 334
Lawrence 333
Singapore 291
San Mateo 252
Novara 245
Ann Arbor 241
Beijing 238
Piemonte 216
Ashburn 156
Andover 130
Boardman 104
Milan 95
Houston 77
Brno 73
Woodbridge 71
Munich 68
Bremen 65
Turin 64
Dong Ket 60
Nanjing 56
Hefei 49
Vercelli 47
Helsinki 42
Philadelphia 39
Düsseldorf 38
Brussels 37
Norwalk 33
Pardubice 32
Kunming 28
Kocaeli 27
Santa Clara 27
Seattle 25
Torino 23
Monmouth Junction 20
Rome 20
Mülheim 19
Fairfield 18
Jinan 18
Nanchang 18
Alessandria 17
Strasbourg 17
Ardabil 16
Cassano Magnago 16
Guangzhou 16
Leawood 15
Toronto 14
West Jordan 14
Zanjan 14
České Budějovice 14
Augusta 13
Grafing 13
Chennai 12
Shenyang 10
Fuzhou 9
Odalengo Grande 9
Paris 9
Villa Cortese 9
Zhengzhou 9
Alba 8
Bologna 8
Lancenigo-Villorba 8
Montreal 8
New York 8
Redwood City 8
Suwon 8
Amsterdam 7
Berlin 7
Brescia 7
Frankfurt am Main 7
Genoa 7
Royal Leamington Spa 7
Sham Shui Po 7
Shanghai 7
Stankov 7
Wuhan 7
Borgomanero 6
Nairobi 6
Palermo 6
Verona 6
Cambridge 5
Chimbote 5
Hebei 5
Kraków 5
Menlo Park 5
Naples 5
Ningbo 5
Stresa 5
Vancouver 5
Xian 5
Canegrate 4
Changsha 4
Chengdu 4
Los Angeles 4
Macao 4
Totale 10.954
Salva come PNG Salva come JPEG
Nome #
Midterm functional sequelae and implications in rehabilitation after COVID19. A cross-sectional study 225
Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients 142
Role of beta-blockers in patients with COPD: current perspective. 110
Simple Parameters from Complete Blood Count Predict In-Hospital Mortality in COVID-19 101
Testosterone Plasma Concentration is Associated with Insulin Resistance in Male Hypertensive Patients 100
B2-Lymphocyte responses to oxidative stress-derived antigens contribute to the evolution of nonalcoholic fatty liver disease (NAFLD) 95
Gas6 as a predictor of esophageal varices in patients affected by hepatitis C virus related-chronic liver disease 94
Change over time of COVID-19 hospital presentation in Northern Italy 94
Validation of the Hepatoma Arterial Embolization Prognostic Score in European and Asian Populations and Proposed Modification. 93
Genistein and 17β-Estradiol Protect Hepatocytes from Fatty Degeneration by Mechanisms Involving Mitochondria, Inflammasome and Kinases Activation 92
Contribution of Atrial Fibrillation to In-Hospital Mortality in Patients With COVID-19 91
Liver infection and COVID-19: the electron microscopy proof and revision of the literature 85
Levosimendan inhibits peroxidation in hepatocytes by modulating apoptosis/autophagy interplay. 85
Antiviral treatment of hepatitis C improves glucose metabolism along the entire spectrum from normal glucose tolerance to diabetes 81
rs1801253 Gly/Gly carriage in the ADRB1 gene leads to unbalanced cardiac sympathetic modulation as assessed by spectral analysis of heart rate variability 80
Gas6/TAM system: A key modulator of the interplay between inflammation and fibrosis 80
Red cell distribution width and platelet count as biomarkers of pulmonary arterial hypertension in patients with connective tissue disorders 80
Altered glucose metabolism rather than naive type 2 diabetes mellitus (T2DM) is related to vitamin D status in severe obesity. 79
Influence of age on sex-related differences among patients with hepatitis C. 78
Treatment failure after interferon-free treatment of hepatitis C as a clue of a yet undetected hepatocellular carcinoma 78
Prediction of serum markers of fibrosis by levels of circulating intercellular adhesion molecule-1 in acute and chronic liver disease 76
Value of serum C-reactive protein measurement in the detection of hepatocellular carcinoma superimposed on liver cirrhosis 76
Interferon alpha concentrations in blood and peritoneal fluid during treatment for hepatitis C 75
Relation among anti-rheumatic drug therapy, CD14(+)CD16(+) blood monocytes and disease activity markers (DAS28 and US7 scores) in rheumatoid arthritis: A pilot study. 75
Pattern of emergency department referral during the Covid-19 outbreak in Italy 75
17,β-estradiol inhibits hepatitis C virus mainly by interference with the release phase of its life cycle 73
Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19 73
Acute decompensated heart failure in the emergency department: Identification of early predictors of outcome 72
Association between rheumatic diseases and cancer: results from a clinical practice cohort study 72
Association between red cell distribution width and response to methotrexate in rheumatoid arthritis 72
Anti-envelope antibodies in anti-hepatitis C virus (HCV) positive patients with and without liver disease 71
Reactivity to B cell epitopes within hepatitis C virus core protein and hepatocellular carcinoma 71
Non-specific increase of serum carbohydrate antigen 19-9 in patients with liver disease is predicted by circulating levels of adhesion molecules 71
Is cholecalciferol a potential disease modifying anti-rheumatic drug for the management of rheumatoid arthritis? 71
Prediction of jaundice by markers of inflammation in patients with liver disease 70
Role of positron emission tomography in the assessment of disease burden and risk of relapse in patients affected by giant cell arteritis 70
Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients 70
Analysis of beta1 and beta2-adrenergic receptors polymorphism in patients with apical ballooning cardiomyopathy 69
One-Year Follow up of Noninvasive Respiratory Support in General Wards 68
High prevalence of infection with hapatitis G virus in patients with hepatic and extrahepatic malignancies 67
Association between vitamin D receptor genetic polymorphisms and acute cellular rejection in liver-transplanted patients 67
Diagnostic value of FibroTest with normal serum aminotransferases 67
Improvement of insulin sensitivity in diabetic and non diabetic patients with chronic hepatitis C treated with direct antiviral agents 67
Response rates to direct antiviral agents among hepatitis C virus infected patients who develop hepatocellular carcinoma following direct antiviral agents treatment 67
Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge 67
Recipient interleukin-28B Rs12979860 C/T polymorphism and acute cellular rejection after liver transplantation: role of the calcineurin inhibitor used. 66
Evaluation of the red cell distribution width as a biomarker of early mortality in hepatocellular carcinoma 66
On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study 66
Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib 66
Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: A multi-center comparative study 66
Inflammatory markers predict insulin sensitivity in active rheumatoid arthritis but not in psoriatic arthritis 66
(Letter) Membranoproliferative glomerulonephritis associated with Hepatitis C infection with no evidence of liver disease 65
Ultrasound-assessed visceral fat and associations with glucose homeostasis and cardiovascular risk in clinical practice 65
Oxidative Stress in Non-Alcoholic Fatty Liver Disease 65
Peroxisome proliferator-activated receptor-gamma expression in monocytes/macrophages from rheumatoid arthritis patients: relation to disease activity and therapy efficacy--a pilot study 64
Severity of nonalcoholic fatty liver disease in type 2 diabetes mellitus: Relationship between nongenetic factors and PNPLA3/HSD17B13 polymorphisms 64
Outcomes of COVID-19 patients treated with continuous positive airway pressure outside ICU 64
Evaluation of circulating activin-A as a serum marker of hepatocellular carcinoma 63
Natural history and risk stratification of patients undergoing non-invasive ventilation in a non-ICU setting for severe COPD exacerbations 63
Patterns of infections in older patients acutely admitted to medical wards: data from the REPOSI register 63
Increased plasma levels of Gas6 and its soluble tyrosine kinase receptors Mer and Axl are associated with immunological activity and severity of lupus nephritis 63
Long-term sequelae are highly prevalent one year after hospitalization for severe COVID-19 63
Endotoxin priming worsens acute reflux pancreatitis in the rat 62
Circulating intercellular adhesion molecule-1 (clCAM-1) concentration in liver disease 62
Intensity of inflammatory damage and serum lipid peroxide concentrations in liver disease 62
Impaired glucose metabolism in hypertensive patients with/without the metabolic syndrome. 62
Gas6 as a putative noninvasive biomarker of hepatic fibrosis 62
Thrombocytopenia in chronic liver disease corrected by erithropoietin treatment 61
Hypeglycaemia-induced thrombin formation in Diabetes. The possible role of oxydative stress 61
Evidence against a direct role played by transfusion-transmitted virus infection in causing hepatic or hematologic manifestations 61
Endotoxin priming and liver damage by experimental duodenal obstruction in the rat 61
Expression of the interferon-inducible proteins MxA and IFI16 in liver allografts 61
Influence of angiotensin-converting enzyme I/D gene polymorphism on clinical and histological correlates of chronic hepatitis C 61
The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma 61
4. Association between release of tumor necrosis factor and response to interferon therapy in chronic hepatitis C 61
Cardiac dysfunction as an early predictor of portal hypertension in chronic hepatitis C 61
Can apical ballooning cardiomyopathy and anterior STEMI be differentiated based on β1 and β2-adrenergic receptors polymorphisms? 61
Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma 61
Prognostic value of serum alpha-1-antitrypsin in hepatocellular carcinoma 61
Immune suppressive treatment of Berger disease 60
Evidence for a multifactorial control of serum erythropoietin concentration in liver disease 60
Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C 60
IL28B Polymorphism, Blood Interferon-alpha Concentration, and Disease Stage of HCV Mono-infected and HCV-HIV Co-infected Patients. 60
Fibrosis Progression in HCV Carriers with Mild Hepatitis Who Possess the High-Repetition Variant of the DRD4 Gene, a Genetic Marker for Binge-Drinking and Risk-Seeking Behavior: A Longitudinal Study. 60
Significato e valore diagnostico dei sintomi e degli esami di laboratorio 60
Candidate Biomarkers of Liver Fibrosis: A Concise, Pathophysiology-oriented Review 60
AORTIC INVOLVEMENT IN A RETROSPECTIVE COHORT OF LARGE VESSEL VASCULITIS PATIENTS 60
Fibrinogen plasma levels as a marker of thrombin activation: new insights on the role of fibrinogen as a cardiovascular risk factor 60
Letter. Activation of the endogenous interferon sustem, expression of interferon-alpha receptors, and response to interferon therapy in chronic hepatitis C 59
Assessment of liver fibrosis progression in patients with chronic hepatitis C and normal alanine aminotransferase values: the role of the AST to platelet ratio index 59
Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C 59
Long-term remission of corticosteroid- and cyclophosphamide-resistant Henoch-Schönlein purpura with rituximab 59
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program 59
Combinatorial use of single nucleotide polymorphisms to help predict liver fibrosis in patients with hepatitis C infections 59
APOLIPOPROTEIN E GENOTYPES MODULATE FIBROSIS PROGRESSION IN PATIENTS WITH CHRONIC HEPATITIS C AND PERSISTENTLY NORMAL TRANSAMINASES 59
Interplay of PNPLA3 and HSD17B13 Variants in Modulating the Risk of Hepatocellular Carcinoma among Hepatitis C Patients 59
Diagnostic usefulness of acute phase protein measurement in hepatocellular carcinoma 58
Increased serum phospholipase A2 activity in advanced chronic liver disease as an expression in the acute phase response 58
Fatal human pulmonary infection caused by an Angiostrongylus-like nematode 58
Immunosoppressive treatment for idiopathic nephrotic syndrome with corticosteroids and cyclophosphamide 58
Totale 7.119
Salva come PNG Salva come JPEG
Categoria #
all - tutte 101.652
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 101.652
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.109 0 0 0 8 560 456 652 192 415 480 323 23
2020/20212.295 299 7 303 14 327 97 318 50 327 77 364 112
2021/20222.292 101 58 459 229 113 28 168 80 196 104 286 470
2022/20235.506 503 221 277 151 299 446 166 229 2.836 34 223 121
2023/20242.585 140 344 150 76 392 74 484 134 54 86 250 401
2024/2025500 134 66 264 36 0 0 0 0 0 0 0 0
Totale 18.251